Focus on Clozapine Withdrawal- and Misuse-Related Cases as Reported to the European Medicines Agency (EMA) Pharmacovigilance Database
Background: Clozapine is of high clinical relevance for the management of both treatment-resistant schizophrenia and psychotic disturbances with concurrent drug misuse. Although the molecule presents with a range of well-known side-effects, its discontinuation/withdrawal syndrome has been only anecd...
Main Authors: | Stefania Chiappini, Fabrizio Schifano, John Martin Corkery, Amira Guirguis |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-02-01
|
Series: | Brain Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/2076-3425/10/2/105 |
Similar Items
-
Is There a Potential of Misuse for Venlafaxine and Bupropion?
by: Fabrizio Schifano, et al.
Published: (2018-03-01) -
Piloting the UK’s First Home-Office-Licensed Pharmacist-Led Drug Checking Service at a Community Substance Misuse Service
by: Amira Guirguis, et al.
Published: (2020-07-01) -
Editorial: Prescribing Psychotropics: Misuse, Abuse, Dependence, Withdrawal and Addiction
by: Stefania Chiappini, et al.
Published: (2021-04-01) -
Assessing the 2004–2018 Fentanyl Misusing Issues Reported to an International Range of Adverse Reporting Systems
by: Fabrizio Schifano, et al.
Published: (2019-02-01) -
Neuroleptic malignant syndrome and subsequent clozapine-withdrawal effects in a patient with refractory schizophrenia
by: Cheng MF, et al.
Published: (2016-03-01)